focus -WSS

focus

author：focus 2025-09-28 02:29:41 - browse：45516

Neumora, a privately held biotech company, is moving into the final phase of testing with a novel treatment for depression that showed promise in a mid-stage trial.

The drug, a daily pill called navacaprant, led to statistically significant improvements over placebo on a measurement of disease severity for patients with moderate to severe major depressive disorder, Neumora said Tuesday. In the eight-week study, the medicine also led to improvements in patient-reported anhedonia, a reduced ability to experience pleasure that often accompanies severe depression.

Navacaprant’s statistically significant benefits came from a pre-specified subset of 100 patients in a study that enrolled 171 people. In the total population, including 71 patients who had mild to moderate disease, navacaprant’s effect on depressive symptoms was numerically superior to placebo but did not reach the threshold of statistical significance, missing the study’s primary endpoint.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： TikTok, Instagram influencers need more rules for drug ads

WSS

A new deal aims to ramp up use of AI in rehab care decisions

Microsoft launches AI tool for clinical documentation through Epic

Mass General, Mayo Clinic look to monetize custom

Washington Commanders' Dan Snyder ordered to pay NFL $60M following investigation

A former Republican legislative candidate has been charged for his role in the US Capitol riot

There's an unseen cost to disruptive road

focus

focus

explore

Trump demands the U.S. pay no more for drugs than other countries … again

EMA weighs against approval for Mirati's lung cancer drug

As demand for Covid shots wanes, Moderna seeks its next success

Immunocompromised patients offer clues on chronic Covid

Supreme Court strikes down use of affirmative action

Dog Aging Project founders on what lies ahead after losing funding

Dobbs anniversary: the lost opportunity of abortion as health care

Mega Millions jackpot grows to $720 million ahead of Friday's drawing

Drug repurposing or repositioning? The language matters

HPV vaccine, cervical cancer study delivers historic results

focus

Suspects arrested after 3 women attacked on Manhattan's West Side: Police

Microsoft launches AI tool for clinical documentation through Epic

Why Marc Tessier

Biden, Billy Joel, Elton John lead tributes for Tony Bennett after singer's death at 96

Update the Apgar Score to remove skin color

Listen: BridgeBio's big week & Lilly's Alzheimer's data

explore

leisure time

knowledge

entertainment